Discussion about this post

User's avatar
Manjari Narayan's avatar

I'm really excited that adaptive trial design is finally getting noticed instead of being a niche topic that only elite cancer trialists get excited about.

Have you seen the new program from ARPA-H?

https://arpa-h.gov/research-and-funding/programs/adapt

They hope to spur development of adaptive biomarkers for evolving metastatic cancers with the kind of trial design that ought to be the gold standard for precision medicine.

Expand full comment
Dr. Shelby's avatar

Really enjoyed reading + love the clinical context of the ctDNA seq advancement.

Expand full comment

No posts